- New drugs take aim at one of cancer’s deadliest mutations Nature
- Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant The ASCO Post
- Breakthrough drugs could finally tackle deadliest ‘undruggable’ cancer mutation thenews.com.pk
- Erika Hamilton on Advancing KRAS G12D Targeting in Lung and Pancreatic Cancer Oncodaily
- Florida Cancer Specialists & Research Institute Contributes to Phase 1 Study Demonstrating Antitumor Activity with First-in-Class KRAS-Targeted Therapy for Treatment of Lung and Pancreatic Cancers PR Newswire
First Appeared on
Source link
